ArticleJVS-vascular science2026
Thrombogenicity of stent graft materials as a potential contributing factor to limb graft occlusions.
Article in JVS-vascular science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Limb graft occlusions (LGOs) remain a significant complication after endovascular aneurysm repair. Several clinical risk factors have been recognized, but these do not fully account for the consistently observed different LGO rates among major commercial stent graft systems. This paper investigates the thrombogenicity of stent graft materials as a potential factor for thrombus formation and therefore LGO. Methods: The thrombogenicity of the graft materials from three commercially available stent grafts (Zenith Alpha, Endurant, and Excluder) was evaluated in vitro using whole blood from four human donors for 1 hour in a dynamic setup. Samples were examined qualitatively with scanning electron microscopy, and the blood was further evaluated quantitatively via enzyme-linked immunosorbent assays for key indicators of thrombogenesis: normalized platelet count in the blood as measure of platelets in the clot, thrombin-antithrombin complex (TAT), β-thromboglobulin (βTG), and the soluble complement membrane attack complex (sC5b9). Results: Qualitative analysis revealed voluminous blot clot formation on Zenith Alpha stent grafts, some blood components on Endurant fabric, and minimal thrombotic factors on Excluder fabric. Material from the Zenith Alpha exhibited the lowest normalized platelet count in the blood ( Conclusions: The materials used in three commercial stent graft systems have significantly different in vitro thrombogenic properties and thrombus formation on the fabrics. Clinical relevance: The found variations of material thrombogenicity between the Zenith Alpha, Endurant, and Excluder stent grafts appear to align with their reported clinical limb graft occlusion rates of these devices. By considering material thrombogenicity and thus thrombus formation, clinicians gain a deeper understanding of device-specific risks that may guide stent graft selection and postprocedural management. In general, these findings exemplify the potential relationship between implantable material properties and clinical complications, which remains insufficiently explored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.